Dig Dis Sci 54:20702083 Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov D, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Vrcic H, Sebecic B (2014) Stable gastric pentadecapeptide BPC 157-NO-system relation
When to reassess If GI symptoms worsen instead of improving over the first 2-3 weeks of a step, if dysesthesia appears suddenly, or if you cannot keep food down, pause and consult a qualified clinician
Why this trial matters: Provides real-world evidence on first-line regimens in a poor-prognosis mCRC subtype Highlights superior survival with chemo + anti-VEGF versus chemo alone or targeted therapy Reinforces the importance of personalized treatment strategies and further trials Eli Lilly Retatrutide Delivers Unprecedented Weight Loss in Phase III TRIUMPH-4 Trial Eli Lillys investigational triple-agonist retatrutide produced an average ~28.7% body-weight reduction (71.2 lbs) at 68 weeks in the Phase III TRIUMPH-4 obesity trial, along with meaningful knee osteoarthritis pain relief, marking one of the strongest weight-loss results reported in late-stage obesity research
It stimulates the production of collagen, elastin, and glycosaminoglycans (GAGs)
CJC-1295 $125/month What Is CJC-1295
Isotretinoin (formerly known as Accutane) is used for the treatment of severe cystic acne
